Hims & Hers Health, Inc. (NYSE:HIMS) Shares Purchased by Xponance Inc.

Xponance Inc. increased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 98.3% in the first quarter, according to its most recent filing with the SEC. The fund owned 27,960 shares of the company's stock after acquiring an additional 13,857 shares during the period. Xponance Inc.'s holdings in Hims & Hers Health were worth $826,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in Hims & Hers Health in the fourth quarter worth approximately $18,048,000. O Shaughnessy Asset Management LLC bought a new position in shares of Hims & Hers Health during the 4th quarter worth $208,000. Commonwealth Equity Services LLC increased its stake in shares of Hims & Hers Health by 111.6% during the fourth quarter. Commonwealth Equity Services LLC now owns 58,894 shares of the company's stock valued at $1,424,000 after buying an additional 31,062 shares during the period. PNC Financial Services Group Inc. increased its stake in shares of Hims & Hers Health by 51.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company's stock valued at $417,000 after buying an additional 5,885 shares during the period. Finally, Amundi raised its holdings in shares of Hims & Hers Health by 49.1% in the fourth quarter. Amundi now owns 12,741 shares of the company's stock valued at $328,000 after acquiring an additional 4,197 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company's stock.

Insider Buying and Selling

In other news, insider Soleil Boughton sold 2,572 shares of the business's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $47.82, for a total value of $122,993.04. Following the completion of the transaction, the insider owned 158,165 shares of the company's stock, valued at $7,563,450.30. The trade was a 1.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Irene Becklund sold 8,485 shares of the business's stock in a transaction that occurred on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $506,978.75. Following the completion of the transaction, the insider directly owned 712 shares of the company's stock, valued at $42,542. The trade was a 92.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 633,126 shares of company stock valued at $33,717,663 in the last 90 days. 13.71% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Bank of America increased their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock an "underperform" rating in a report on Tuesday, April 29th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC reissued a "hold" rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Piper Sandler restated a "neutral" rating and set a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday, May 7th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $39.83.

Hims & Hers Health Price Performance

Hims & Hers Health stock traded up $0.37 during midday trading on Friday, reaching $50.36. The company's stock had a trading volume of 22,012,686 shares, compared to its average volume of 24,108,631. Hims & Hers Health, Inc. has a 52-week low of $13.47 and a 52-week high of $72.98. The stock has a market capitalization of $11.27 billion, a P/E ratio of 72.99, a PEG ratio of 1.91 and a beta of 2.02. The stock's 50-day simple moving average is $53.86 and its 200-day simple moving average is $41.62.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company had revenue of $586.01 million during the quarter, compared to analysts' expectations of $535.21 million. During the same period last year, the business earned $0.05 EPS. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. As a group, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.